Clinical Relevance of Relative Receptor Binding Affinity: Quetiapine and Ziprasidone as Examples

S. Preskorn

DOI: https://doi.org/10.1097/01.pra.0000300125.22064.a9

2007-11-01

Journal of Psychiatric Practice

Abstract:November 2007 393 The last column in this series on antipsychotics focused on the early history of antipsychotics, from reserpine and chlorpromazine to haloperidol.1 This column returns to the issue of relative binding affinity, which was first discussed with reference to antidepressants in a column almost a decade ago.2 The focus of this column will be antipsychotics, using quetiapine and ziprasidone as examples to illustrate the clinical relevance of relative receptor binding affinity. This discussion will set the stage for subsequent columns that will discuss the concept of “atypical” antipsychotics. The regular reader will recognize Equations 1 and 2 (see next page), which are hallmarks of this column. Equation 1 shows that the effect of any drug is a function of three variables: 1) its affinity for and intrinsic activity at one or more sites of actions (almost always a regulatory protein), 2) the concentration achieved at that (or those) site(s) of action, and 3) the specific biology of the patient being treated. Equation 2 specifies that the concentration achieved at that (or those) site(s) of action is in turn determined by the dosing rate going into the patient divided by the ability of that specific patient to clear the drug from his or her body.